SGMO News and Press, Sangamo Therapeutics Inc. From 02/08/22

Sangamo Therapeutics (NASDAQ:SGMO) said preliminary data from a phase 1/2 study, dubbed STAAR, of its gene therapy isaralgagene civaparvovec (ST-920) continued to be well tolerated in patients with Fabry disease. Fabry disease is a rare inherited disorder of glycosphingolipid (fat) metab...

- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean no...

The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patien...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on Monday, January 10 th at 7:00 a.m. Eastern Time. The virtual session may be access...

Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe ...

- No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required blood transfusions post engraftment Sangamo Therapeutics, Inc. (Nasdaq: SGM...

Sangamo Therapeutics is ready to present data from their sickle cell and hemophilia A gene therapy programs at ASH. I believe the data could trigger a reversal by year-end. I discuss why I believe the ASH data is so important for both the near-term and long-term outlook for the stock....

CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...

Image source: The Motley Fool. Sangamo Therapeutics, inc (NASDAQ: SGMO) Q3 2021 Earnings Call Nov 4, 2021 , 9:15 a.m. ET Operator Continue reading For further details see: Sangamo Therapeutics, inc (SGMO) Q3 2021 Earnings Call Transcript ...

Sangamo Therapeutics, Inc. (SGMO) Q3 2021 Earnings Conference Call November 4, 2021 9:15 AM ET Company Participants Aron Feingold – Head-Corporate Communications Sandy Macrae – Chief Executive Officer Prathyusha Duraibabu – Chief Financial Officer Bettina Cockroft –...